Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,65
KB0,52
PKN122,88122,98-1,97
Msft5,71
Nokia11,42511,45-6,92
IBM5,17
Mercedes-Benz Group AG43,39543,4-2,91
PFE2,62
26.06.2026 22:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 23.06.2026 15:46:15
Bavarian Nordic (BAVA.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
23,54 -0,34 -0,08 94
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.06.2026
Popis společnosti

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Bavarian Nordic A/S revenues decreased 21% to DKR1.06B. Net income decreased 92% to DKR17M. Revenues reflect Sale of goods - MVA-BN smallpox vaccine sale segment decrease of 53% to DKR293.7M, Sale of goods - other product sale segment decrease of 90% to DKR5.4M. Net income also reflects Administrative increase of 26% to DKR160.8M (expense).



  • Poslední aktualizace: 26.06.2026
Management společnosti